ABSTRACT
Fibromatosis (also termed desmoid-type fibromatosis) of the breast is a rare neoplasm (<1% of breast lesions) composed of fibroblasts and myofibroblasts, arising either within the breast parenchyma or the pectoral fascia of the chest wall. The morphologic features and immunohistochemical profile of mammary fibromatosis have been well documented in previous case series. [1] [2] [3] [4] Abnormalities in the APC gene occur in familial cases (associated with familial adenomatous polyposis [FAP] ) and in some sporadic tumors. 5 Activating mutations in the β-catenin gene (CTNNB1) are found in most sporadic tumors. 5, 6 Alterations in either gene change the regulation of β-catenin, resulting in stabilization and aberrant accumulation of this oncoprotein in the nucleus.
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• recognize the clinical and radiologic findings of fibromatosis of the breast.
• list the most common differential diagnoses and useful immunohistochemical markers to distinguish fibromatosis from other morphologic mimickers.
• discuss the clinical significance of incomplete excision and summarize the changing trends in management of these lesions.
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Clinically and radiologically, fibromatosis can closely mimic malignancy by forming a mass, often with irregular, invasive margins. Core needle biopsy (CNB) is frequently performed for diagnosis.
Standard treatment, at least historically, has been complete excision with the intention to obtain margins free of tumor. Observational studies, however, show that these tumors can be stable over time, and surgical series find that margin status does not accurately predict recurrence. [7] [8] [9] In addition, it has been found that margin status is a poor predictor of recurrence. Observation by clinical examination and breast imaging after diagnosis by CNB has become standard practice in many high-volume sarcoma centers. In this setting, it is important to know the reliability of a diagnosis of fibromatosis on CNB. The aim of this study was to evaluate the accuracy of CNB for diagnosing fibromatosis by reviewing cases that had subsequently undergone excision.
Materials and Methods
The pathology database of Brigham and Women's Hospital (BWH) and Brigham and Women's Faulkner Hospital (BWFH) was searched over the period of 1997 to 2016 for cases in which fibromatosis of the breast had been diagnosed or included in the differential diagnosis on a CNB, an excision, or both. Specimens obtained at either institution or reviewed in consultation were included. Consult cases in which both the CNB and excision had been simultaneously reviewed were excluded, as well as recurrences and lesions located outside of the breast or anterior chest wall. Anterior chest wall lesions were included when the patient had a history of mastectomy. Clinical presentation, including age at diagnosis, and imaging findings, morphologic and immunohistochemical (IHC) results (performed either at BWH or BWFH or at the original institution) from CNB, and excision were reviewed from pathology reports and electronic medical records. Institutional review board approval at BWH was obtained for this study.
Results

Patient Characteristics
A total of 31 patients undergoing a CNB and a subsequent excision were identified ❚Table 1❚. All patients were female with a median age at diagnosis of 45 years (range, 16-81 years). Two patients had a history of FAP at diagnosis, with additional desmoid tumors documented elsewhere. Most of the lesions were located in the breast, with only two located in the anterior chest wall. These two patients developed fibromatosis after previous mastectomies for invasive ductal carcinoma (IDC) and lobular carcinoma in situ (LCIS). The latter patient also underwent reconstruction with implants. There were four additional patients with fibromatosis with a history of breast surgery for invasive carcinoma (n = 1), in situ carcinoma (n = 2), or reduction mammaplasty (n = 1). The median time between diagnostic biopsy and excision was 1.34 months (range, 0.3-36.7 months). Most patients had an excision within 6 months of diagnosis (24/31, 77%).
Clinical Presentation and Imaging Findings
The most common presentation was a mass (n = 28, 90%), either palpable or screening detected (median size, 1.4 cm; range, 0.5-6.8 cm). The margins were described radiographically for 17 lesions and were indistinct or obscure in 47%, irregular or spiculated in 35%, and circumscribed in 18%. Two patients had architectural distortion, and one patient with a magnetic resonance imaging (MRI) study showed nonmass enhancement. The patient with a previous mastectomy for IDC developed a palpable mass associated with the mastectomy scar. The patient with a history of LCIS and postmastectomy reconstruction had a palpable mass that was anatomically separate from the implant.
Pathologic Findings
There were 18 cases with a definitive diagnosis of fibromatosis on CNB, and 17 (94%) were confirmed as fibromatosis on excision (Table 1 , cases 1-18). Nuclear positivity for β-catenin was confirmed in 14 cases and the absence of CD34 in 11 cases ❚Image 1❚. High molecular weight cytokeratin and/or p63 were used to exclude spindle cell carcinoma in 13 cases. Fourteen patients underwent excision within 4 months. Two patients with FAP underwent delayed excision when other lesions were also excised. One patient showed increased density of the lesion at 6-month imaging follow-up and elected excision at that time.
The single case of fibromatosis diagnosed on CNB but not confirmed on excision had several unusual features. This was the only case that presented as nonmass enhancement on MRI. Although a diagnosis of fibromatosis was rendered and nuclear β-catenin was observed, it was also noted that the positive result for CD34 staining was unusual. The lesion was not excised. Over a 3-year period, the area became denser by imaging and by clinical examination. Subsequent excision showed a borderline phyllodes tumor. Only nuclear immunoreactivity for β-catenin was considered a positive result.
Nine cases included fibromatosis in the differential diagnosis on CNB, and fibromatosis was subsequently confirmed in five (56%) cases (Table 1 , cases [19] [20] [21] [22] [23] [24] [25] [26] [27] . The other diagnoses were cellular myofibroblastic proliferation, sclerosing papilloma, scar, and a benign phyllodes tumor. Immunohistochemical studies were performed on CNB in only two of the cases of fibromatosis, and both showed absence of nuclear β-catenin, which is uncommon but seen in up to 20% of fibromatoses. 10 Both excisions showed typical morphologic features of fibromatosis with long sweeping fascicles of bland spindle cells entrapping normal breast lobules and fat. Nuclear β-catenin expression was documented on excision in one case. This lesion was CD34 negative. Immunoperoxidase studies were not performed on two consult cases and one case from 1998.
The final four cases of fibromatosis on excision were diagnosed as other lesions on CNB (Table 1 , cases 28-31). In three cases with diagnoses of dense fibrous tissue, scar, or hypertrophic scar, the lesion was excised due to the lack of a specific diagnosis. Only one of the patients had a history of surgery. Immunohistochemical studies were performed in one case and showed absence of nuclear β-catenin. The final case was diagnosed as nodular ❚Image 1❚ Typical findings of fibromatosis on core needle biopsy. A, At low power (×40), sweeping fascicles of spindle cells infiltrate into the adjacent breast parenchyma. B, The spindle cells show minimal nuclear pleomorphism and mitoses are not seen (×100). C, Aberrant nuclear immunoreactivity for β-catenin supports the diagnosis. Note the adjacent epithelium with normal membrane staining (×200). D, The lesional cells are negative for CD34, whereas the adjacent normal stromal cells are positive (×200).
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Margin status was available in 24 of the 26 excisions with fibromatosis. Eighteen (75%) cases had positive margins on excision, and in three (13%) cases, the lesion was less than 0.1 cm from margins. Reexcision was performed on only two cases with positive margins, with final margins being free of tumor. No documented residual or recurrent disease was found for 20 cases with follow-up (17 cases with positive or close margins and three with negative margins; median follow-up, 13.4 months; range, 0.7-220.8 months). Two cases with positive margins with short follow-up (less than 2 months) had findings suspicious for residual disease on MRI, but postsurgical changes were not excluded. These patients were to be followed by imaging rather than immediate reexcision.
Discussion
Fibromatosis is a rare breast lesion. The diagnosis on CNB can be challenging due to a wide range of possible benign and malignant spindle cell lesions. [11] [12] [13] Three prior studies of mammary fibromatosis included small numbers of cases sampled by CNB (5, 7, and 12 cases). 4, 6, 14 Only two of the 24 cases were reported to have been specifically diagnosed as fibromatosis on CNB. However, these studies were not designed to evaluate diagnosis on CNB. The current study presents the largest number of cases of fibromatosis sampled by CNB and the first study to investigate diagnostic accuracy. Of the 26 cases of fibromatosis, 17 (65%) were accurately diagnosed on CNB and 5 (19%) included fibromatosis in the differential diagnosis. The remaining four cases were mistaken for other benign lesions.
The imaging and clinical findings of fibromatosis are not distinctive and, in fact, are similar to malignant lesions. Fibromatosis often forms a mass with irregular or spiculated margins or architectural distortion. 15 In this study, 25 of the cases of fibromatosis presented as masses-at least 15 were palpable, and five had irregular or spiculated margins. The final case was detected as an area of architectural distortion. Biopsy is essential to exclude a malignant diagnosis.
Fibromatosis is sometimes associated with a history of trauma, surgery, and/or breast implants. 4 In this study, six (23%) of the 26 patients with fibromatosis had a history of breast surgery. Two of the lesions arose in the chest wall after mastectomy. However, as previously reported in other series, most lesions arose de novo. 1, 4 Fibromatosis is primarily diagnosed based on morphologic features. However, immunohistochemical studies are helpful to support the diagnosis, especially when only limited lesional tissue is present in a CNB. [11] [12] [13] Aberrant nuclear expression of β-catenin is a helpful marker for fibromatosis and is associated with the genetic alterations commonly found in this lesion. 5, 6 Both familial and sporadic cases show nuclear positivity in approximately 80% of cases. However, this finding is not specific as it can also be seen in other breast lesions, including phyllodes tumors (~60%-95% of cases) and rarely in spindle cell carcinomas. 10, 11, 16 The absence of CD34 can also support the diagnosis of fibromatosis. Most normal stromal cells and stromal cell lesions of the breast express CD34. The only stromal breast lesions that typically do not express CD34 are fibromatosis and nodular fasciitis. 11, 12, 17 Other markers expressed in fibromatosis are smooth muscle actin and desmin, but these are nonspecific and can be expressed in a variety of other breast lesions. 3, 12 In this study, the combination of β-catenin and CD34 was performed in 11 of the 26 cases of fibromatosis. In the remaining 15 cases, one or both of these markers were not performed. Six of these cases were consults, one occurred in a patient with FAP (with known desmoid tumors), and two were diagnosed prior to the common use of β-catenin (implemented at BWH for clinical use in 2004). It is possible that a definitive diagnosis of fibromatosis could have been made in more cases with greater use of immunohistochemical studies.
Three (18%) of 17 cases of fibromatosis did not show nuclear positivity for β-catenin. Two cases included fibromatosis in the differential diagnosis, and one was diagnosed as dense fibrous tissue. In these cases, deferring a definitive diagnosis to excision may be preferable due to this less typical result. 10 The 12 cases of fibromatosis that were tested for CD34 were negative. Only one case diagnosed as fibromatosis on CNB showed positivity for CD34 ❚Image 2❚. The lesion was later shown to be a phyllodes tumor on excision. In retrospect, the CNB showed an area of stromal overgrowth lacking the epithelial component that would have aided in recognizing the lesion as a phyllodes tumor. CD34 expression has not been reported in mammary fibromatosis, and its absence is a useful finding to support the diagnosis.
The most important diagnosis to exclude in a CNB with a spindle cell lesion is spindle cell carcinoma. Fibromatosislike metaplastic carcinoma can be challenging as these malignancies resemble a benign spindle cell proliferation but often have areas with plump spindle cells or epithelioid cells. 11, 18 A panel of cytokeratin antibodies, including broad-spectrum cytokeratins and particularly high molecular weight cytokeratins, is recommended since these tumors can show focal or no immunoreactivity with some antibodies. 11, 18, 19 Breast carcinomas with a spindle cell component are often positive for p63, and this is also a useful marker. 20 Carcinomas may rarely show nuclear β-catenin positivity but are typically negative for CD34. Fifteen of the cases of fibromatosis in the current series were tested for high molecular weight keratin and/or p63, and all were negative.
Other morphologic mimickers include scar, phyllodes tumor, and fascicular pseudoangiomatous stromal hyperplasia (PASH). To exclude these differential diagnoses, immunohistochemical studies can sometimes be helpful. Scars and PASH are positive for CD34 and negative for β-catenin.
11 While phyllodes tumors may show nuclear β-catenin expression in up to 72% of cases, 21 CD34 positivity and, if present, the association of a glandular component with the spindle cell stroma can favor this diagnosis.
Surgical excision with the intent to achieve negative margins has long been the traditional treatment for fibromatosis. 22 Recurrence has been associated with location (trunk) and size (>10 cm) 23 but not with positive margins in primary disease. 22 Despite the high rate of positive margins (75%) observed in our cohort, we found no definitive ❚Image 2❚ Borderline phyllodes tumor mistaken for fibromatosis on core needle biopsy. A, At low power (×40), an area of stromal overgrowth without associated epithelium mimics fibromatosis. B, The spindle cells show minimal nuclear pleomorphism and mitoses are not seen (×200). C, Aberrant nuclear immunoreactivity for β-catenin is also seen in some phyllodes tumors (×200). D, The lesional cells are positive for CD34 (×200). This is a common finding in phyllodes tumors but has not been reported in fibromatosis.
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AJCP / Original article recurrences in a median follow-up of approximately 1 year. The recognition that many cases of fibromatosis do not progress has supported a more conservative approach of observation in patients with asymptomatic lesions that are not located in an area where tumor growth could lead to functional limitations. [7] [8] [9] 24 In some instances, fibromatoses present after progression to a point where surgery is not possible without significant loss of function. This situation is more commonly encountered for tumors located in the small bowel mesentery, deep pelvis, or adjacent joints. CNB is also important to establish diagnosis in these cases, as they can be successfully treated with chemotherapy. 8, [25] [26] [27] This study has shown that a diagnosis of fibromatosis can be made reliably in most cases on CNB. These lesions present as sweeping fascicles of bland spindle cells with a variable amount of collagen deposition. They usually have an infiltrative pattern, entrapping fat and normal breast lobules. Immunohistochemical studies are helpful to support the diagnosis and to exclude carcinoma. Nuclear β-catenin expression and negative CD34 and keratin stains are the most helpful studies to support this diagnosis. Therefore, misdiagnosis of fibromatosis on CNB would likely be avoided by greater use of IHC, as well as attention to expression patterns not typical for fibromatosis. There were no cases of fibromatosis mistaken for a malignant lesion or a malignant lesion mistaken for fibromatosis. Observation without excision after CNB could be appropriate conservative clinical management, with excision being reserved for lesions that increase in size.
